Blair William & CoIl New Position in EXACT Sciences Corporation (NASDAQ:EXAS)
Blair William & CoIl has filled a SC 13G/A form regarding Exact Sciences Corp 28.17 0.00 %. Filing Link: 000114420415040845. Per Blair William & CoIl’s filing, the filler now owns 5.74% of the Health Care-company, holding 5,080,804 shares.
EXACT Sciences Corporation (NASDAQ:EXAS) is a newly disclosed equity position for this institutional investor and the filing was required due to activity on December 31, 2014. This most probably shows Blair William & CoIl’s confidence and optimism in the future of the company.
Exact Sciences Corp Hedge Funds Ownership
Latest SEC filings show 175 hedge funds and institutional investors own Exact Sciences Corp. The institutional ownership of the company in Q1 2015 is high, at 96.99% of the shares outstanding. They increased by 301927 the total shares they hold. As of that quarter these institutional investors owned 86234458 shares. A total of 25 funds opened new positions in Exact Sciences Corp and 85 increased their holdings. There were 39 funds that closed their positions and 43 that reduced them.
2 investors have the firm in their Top 10. Some of these are: Cupps Capital Management Llc, J&P(China)Capital Management Co.Ltd..
HEDGE-FUNDS-LIST-DATABASE-FREE Beach Investment Counsel Inc is the most positive institutional investor on Exact Sciences Corp, with ownership of 18575 shares as of Q1 2015 for less than 0.01% of the fund’s portfolio. Jane Street Group Llc is another positive player owning 10685 shares of the company or less than 0.01% of their stocks portfolio. KS Mitchell Capital Management Co have 0.79% of their stock portfolio invested in the stock for 116498. Further, Primecap Management Company disclosed it had purchased a stake worth 0.05% of the fund’s stock portfolio in the company. The IL Cupps Capital Management Llc was also a notable investor in the firm, owning 1262593 shares. Exact Sciences Corp is 2.47% of the fund’s stock portfolio.
Company Profile
Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of colorectal cancer. The Company has developed a non‑invasive screening test called Cologuard for colorectal cancer. Its Cologuard test is a non‑invasive stool‑based deoxyribonucleic acid (DNA) (sDNA) screening test designed to detect DNA markers. In addition to DNA markers, its test includes a protein marker to detect blood in the stool, utilizing an antibody‑based fecal immunochemical test (FIT). The Company’s Cologuard test is designed to detect pre‑cancerous lesions or polyps, and each of the four stages of colorectal cancer. By detecting pre‑cancers and cancers early with its test, affected patients can be referred to colonoscopy, during which the polyps or lesions can be removed. The company’s test also detects blood in stool, utilizing an antibody based FIT test.
Form 13G is used when the filer owns between 5% and 20% of the company and plans to hold it only as a passive investor. If the filler intend to exert control and if the stake’s size exceeds 20%, then a 13D must be filed. Therefore, activist investors and practices such as: hostile takeovers, company breakups, and other “change of control” events, are not permitted by 13G filers.
Blair William & CoIl has filled a SC 13G/A form regarding Exact Sciences Corp 28.17 0.00 %. Filing Link: 000114420415040845. Per Blair William & CoIl’s filing, the filler now owns 5.74% of the Health Care-company, holding 5,080,804 shares.
EXACT Sciences Corporation (NASDAQ:EXAS) is a newly disclosed equity position for this institutional investor and the filing was required due to activity on December 31, 2014. This most probably shows Blair William & CoIl’s confidence and optimism in the future of the company.
Exact Sciences Corp Hedge Funds Ownership
Latest SEC filings show 175 hedge funds and institutional investors own Exact Sciences Corp. The institutional ownership of the company in Q1 2015 is high, at 96.99% of the shares outstanding. They increased by 301927 the total shares they hold. As of that quarter these institutional investors owned 86234458 shares. A total of 25 funds opened new positions in Exact Sciences Corp and 85 increased their holdings. There were 39 funds that closed their positions and 43 that reduced them.
2 investors have the firm in their Top 10. Some of these are: Cupps Capital Management Llc, J&P(China)Capital Management Co.Ltd..
HEDGE-FUNDS-LIST-DATABASE-FREE Beach Investment Counsel Inc is the most positive institutional investor on Exact Sciences Corp, with ownership of 18575 shares as of Q1 2015 for less than 0.01% of the fund’s portfolio. Jane Street Group Llc is another positive player owning 10685 shares of the company or less than 0.01% of their stocks portfolio. KS Mitchell Capital Management Co have 0.79% of their stock portfolio invested in the stock for 116498. Further, Primecap Management Company disclosed it had purchased a stake worth 0.05% of the fund’s stock portfolio in the company. The IL Cupps Capital Management Llc was also a notable investor in the firm, owning 1262593 shares. Exact Sciences Corp is 2.47% of the fund’s stock portfolio.
Company Profile
Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of colorectal cancer. The Company has developed a non‑invasive screening test called Cologuard for colorectal cancer. Its Cologuard test is a non‑invasive stool‑based deoxyribonucleic acid (DNA) (sDNA) screening test designed to detect DNA markers. In addition to DNA markers, its test includes a protein marker to detect blood in the stool, utilizing an antibody‑based fecal immunochemical test (FIT). The Company’s Cologuard test is designed to detect pre‑cancerous lesions or polyps, and each of the four stages of colorectal cancer. By detecting pre‑cancers and cancers early with its test, affected patients can be referred to colonoscopy, during which the polyps or lesions can be removed. The company’s test also detects blood in stool, utilizing an antibody based FIT test.
Form 13G is used when the filer owns between 5% and 20% of the company and plans to hold it only as a passive investor. If the filler intend to exert control and if the stake’s size exceeds 20%, then a 13D must be filed. Therefore, activist investors and practices such as: hostile takeovers, company breakups, and other “change of control” events, are not permitted by 13G filers.
This place will be Actavis soon. Sold to the highest bidder!
Aucun commentaire:
Enregistrer un commentaire